Artiva Biotherapeutics

Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. Their lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy that is being evaluated in clinical trials for the treatment of systemic lupus erythematosus (SLE) with or without lupus nephritis, as well as in multiple other autoimmune indications. AlloNK is also being evaluated for the treatment of non-Hodgkin lymphoma, and in combination with Affimed’s innate cell engager acimtamig for the treatment of patients with relapsed/refractory CD30-positive lymphomas.

Artiva differentiates itself by focusing on a "manufacturing-first approach" to develop accessible and scalable cell therapies. This approach leverages a process pioneered by their strategic partner, GC Cell Corporation, and enables the production of off-the-shelf, allogeneic NK cell therapies at a large scale, making them potentially more affordable and available to a wider patient population. Artiva believes their NK cell-based therapies offer significant advantages over traditional cell therapies by potentially providing a safer and more effective treatment option for patients with autoimmune disease and cancer.

Artiva Biotherapeutics offers a comprehensive benefits package designed to support employee health and well-being. This includes medical, dental, and vision insurance, as well as supplemental medical coverage for critical illness, hospital, accident, life insurance, disability, and legal services. For financial well-being, they provide a 401(k) retirement plan, equity/stock options, and flexible spending accounts. Work-life integration is facilitated with generous paid time off, company-paid holidays, parental leave, and a year-end holiday week. Employee recognition is also valued with a peer recognition program, spot bonuses, and achievement awards. They also have an on-site gym, snacks, and great coffee to promote overall well-being.

Artiva Biotherapeutics is a clinical-stage biotechnology company dedicated to developing safe, effective, and accessible natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. They aim to develop therapies that can be readily utilized in a community setting, making cell therapy broadly available to those in need. Their lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy designed to be used in combination with B-cell targeted monoclonal antibodies (mAbs). This approach, coupled with their manufacturing-first strategy, allows them to produce off-the-shelf therapies at scale, potentially revolutionizing the accessibility and impact of cell therapy for a wide range of patients.

Artiva Biotherapeutics promotes a collaborative and supportive work culture where teamwork, tenacity, innovation, transparency, and inclusion are highly valued. The company emphasizes a flat organizational structure with open communication channels to encourage creativity, passion, and a sense of belonging among employees. The company believes in pushing boundaries and working together to achieve its mission of delivering life-saving and life-improving therapies to patients with autoimmune diseases and cancers.

Artiva Biotherapeutics is committed to fostering a diverse and inclusive workplace where all voices are valued and heard. They believe in transparency and open communication paths, and strive to create a supportive environment where talented individuals can contribute their unique perspectives. Artiva actively promotes diversity within their team and recognizes the value of different backgrounds and experiences in driving innovation and achieving their mission.